Dr Deeren discusses the latest update in the management of patients with Paroxysmal Nocturnal Hemoglobinuria including the place of the new long acting C5 inhibitor ravulizumab in the treatment algorithm
Ariez Publishing
Dr Deeren discusses the latest update in the management of patients with Paroxysmal Nocturnal Hemoglobinuria including the place of the new long acting C5 inhibitor ravulizumab in the treatment algorithm
00:00 / 11:02